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Abstract
Biomedical science has made major advances in understanding how cells grow into functioning tissue and
the signalling mechanisms used to achieve this are slowly being dissected. Tissue engineering is the ap-
plication of that knowledge to the building or repairing of organs, including skin, the largest organ in the
body. Generally, engineered tissue is a combination of living cells and a supporting matrix. Besides serving
as burn coverings, engineered skin substitutes can help patients with diabetic foot ulcers. Today, most
of these ulcers are treated with an approach that includes antibiotics, glucose control, special shoes and
frequent cleaning and bandaging. The results of such treatments are often disappointing and ineffectual,
and scarring remains a major problem, mechanically, cosmetically and psychologically. Within our group
we are attempting to address this by investigating novel approaches to skin tissue engineering. We
are identifying novel therapeutic manipulations to improve the degree of integration between a tissue
engineered dermal construct and the host by both molecular manipulation of growth factors but also by
understanding and harnessing mechanisms of regenerative biology. For the purpose of this summary, we
will concentrate primarily on the latter of these two approaches in that we have identiﬁed a novel mouse
mutant that completely and perfectly regenerates skin and cartilaginous components following ear injury.
This experimental animal will allow us to characterize not only novel genes involved in the regeneration
process but also to utilize cells from such animals in artiﬁcial skin equivalents to assess their behaviour
compared with normal cells. This approach should allow us to create a tissue-engineered substitute, which
more closely resembles the normal regional microanatomy and physiology of the skin, allowing better
integration to the host with minimal or no scarring.
Challenges of skin tissue engineering
Tissue engineering can be defined as the development and
manipulation of laboratory grown cells, tissues or organs to
replace or restore the function of defective or injured body
parts. Currently, there is a shortage of organs and tissues
available for transplantation. There are many potential target
organs for manipulation in tissue engineering, including not
only the skin but the eye, liver, pancreas, bone and cartilage as
well as vascular replacement grafts. Designing replacements
to mimic the native tissue will improve the adequacy of tissue
function, ultimately leading to improved patient care at less
expense. The development of clinically useful tissues in vitro
for application in a clinical situation is a complex task, deter-
mined by the nature of the tissues themselves. This com-
plexity is also reflected in the interdisciplinarity of expertise
required to produce such a tissue, in our case, skin. A plat-
form of knowledge needs to be developed between cell and
molecular biologists, biomaterials scientists as well as the
clinicians and surgeons who will utilize the end-products.
Not only do we need a biological understanding of the skin,
equally important is the application of information from
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realistic engineering solutions to the clinical and surgical
problems.
Existing therapies and commercial
products
Cadaver skin is sometimes used as a temporary covering to
protect the patient’s recovering wounds but it is in limited
supply, costly, and variable in quality with many safety con-
cerns, e.g. viruses, transmissible spongiformencephalopathies
etc. The alternative is to graft andmesh an autologous piece of
skin from another unwounded location of the body. Neither
of these approaches is ideal and has led to the development of
alternative, off-the shelf commercial products.
The three main developments in tissue engineering of
the skin are based on research data gained between 25 and
30 years ago. Rheinwald and Green [1] isolated and in vitro
cultured keratinocytes from skin, Genzyme created living
epithelial sheets using this technology, marketed since 1987
as EpiCel R©. Another development based on the study of Bell
et al. [2], uses a collagen matrix seeded with dermal fibro-
blasts and covered with a layer of keratinocytes. This led to
the development of substitutes like Apligraf R©, manufactured
by Organogensis, and Dermagraft R©, created by Advanced
Tissue Sciences. The final development was that of the acellu-
lar dermal substitute, Integra R© by Integra Life Sciences based
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on the work of Burke et al. [3]. Tissue engineering has un-
doubtedly made great advances as a scientific discipline, it
has however, been much less successful as a business. Three
leaders in the industry fell into financial trouble very recently:
Advanced Tissue Sciences, Organogenesis and Integra Life
Sciences have all filed for bankruptcy. The reasons for these
failures are multiple, one of the most cited was process auto-
mation costs. The costs of changing current medical practice
were also identified as were the logistics of selling living
products. However, there are major scientific drawbacks
with existing products, which also need to be addressed.
These include lack of vascularization or ‘take’, scarring, cell
sourcing and persistence, absence of differentiated structures,
biocompatibility and mechanotransductional properties, and
ultimately the cost of both manufacture and supply.
A clinical problem – simple repair or a
regenerative medicine approach?
In human and domestic animals scarring in the skin following
trauma or surgery is a major medical problem. It often re-
sults in adverse aesthetics, loss of function, restriction of
tissue movement and/or growth and adverse psychological
effects [4]. At present, there are no prescription drugs for the
prevention or treatment of dermal scarring.Within our group
we are investigating novel approaches to tissue engineering
in the skin, specifically to assist with the healing of wounds
or replacement of tissue following burn injury. We are also
identifying novel therapeutic manipulations to improve the
degree of integration between a tissue engineered dermal
construct and the host. This approach not only involves ex-
ploiting our prior expertise in the prevention of scarring but
an understanding of regenerative biology and its application
to a tissue engineering problem.
In higher vertebrates, injury to the skin initiates a cascade
of events including inflammation, tissue formation and re-
modelling, which leads to a partial reconstruction of the dam-
aged area. The wound repair process is initiated immediately
following injury and the initial stages of inflammation involve
polymorphonuclear leukocytes, mainly neutrophils, that are
recruited to the wound site where their numbers increase
steadily, peaking by 24–48 h [5]. Their main function appears
to be phagocytosis of the bacteria that have been introduced
into the wound during injury. The next cellular, immune ele-
ment tobe recruited to thewound aremacrophages. They first
appear within 48–96 h post-injury and generally reach a peak
around the third day post-injury. During this time epithelial
cells and keratinocytes migrate across the wound surface
to restore epithelial integrity. T-lymphocytes then appear in
significant numbers around the fifth day post-injury, with
peak numbers occurring about the seventh day after injury.
In contrastwith polymorphonuclear leukocytes, the presence
and activation of both macrophages and lymphocytes in the
wound is critical to the progress of the normal healing pro-
cess [5]. Macrophages release substances that facilitate the re-
cruitment of additional inflammatory cells and aid themacro-
phage in tissue decontamination and debridement; in
addition, growth factors and other substances are also re-
leased, which are necessary for the proliferation phase to
occur. This involves the initiation and propagation of granul-
ation tissue formation, which is composed of fibroblasts and
inflammatory cells, along with new capillaries embedded in a
loose extracellular matrix of collagen, fibronectin, hyaluronic
acid and glycosaminoglycans. As the wound matures, col-
lagen is initially deposited in a random arrangement that
is subsequently reorganized, by cross-linking, into regularly
aligned bundles oriented along the stress lines of the healing
wound [5]. As remodelling progresses, there is a gradual
reduction in the cellularity and vascularity of the reparative
tissue, which results in the formation of a relatively avascular
and acellular collagen scar.
There are, however, molecular differences between scar-
free healing in embryonicwounds and scar-forminghealing in
adult wounds [4]. The inflammatory response in embryonic
wounds consists of lower numbers of less differentiated in-
flammatory cells [6]. This together with high levels of mor-
phogenetic molecules involved in skin growth and morpho-
genesis, means that the growth factor profile in a healing
embryonic wound is very different from that in an adult
wound [7–11]. Thus embryonic wounds that heal without a
scar have low levels of TGFβ1 (transforming growth factor
β1) and β2, low levels of platelet derived growth factor and
high levels of TGFβ3 [4]. We have experimentally manipu-
lated healing adult wounds in mice, rats and pigs to mimic the
scar-free embryonic profile, e.g. neutralizing platelet-derived
growth factor, neutralizing TGFβ1 and TGFβ2 or adding
exogenous TGFβ3 [4,9,10,12–15]. These experiments result
in scar-free wound healing in the adult.
Regeneration can occur in mammals
Regeneration, unlike repair, leads to complete replacement
of the injured structures, resulting in a fully functional, scar-
less, reconstructed tissue. Mammalian regeneration has long
been considered the ultimate goal of the tissue engineering
field. One of the challenges, however, is to understand and
harness basic tissue biology, as well as tissue regeneration
and the cellular and molecular mechanisms responsible for
tissue turnover. Although numerous examples of complete
regeneration exist in invertebrates, higher vertebrates such as
amphibians demonstrate extensive but restricted regenera-
tion, whereas mammals are severely limited in regenerative
capacity.
To date, few examples of true mammalian regeneration
have been described. The rabbit earmodel extensively studied
by Goss and Grimes [16] demonstrated a departure from the
normal mammalian dermal repair process, with extended epi-
thelial proliferation and migration, as well as dermal growth
and the replacement of cartilage. More recently, Clark et al.
[17] described similar ear punch regeneration in the inbred
MRL/MpJ mouse strain. In this model, 2 mm excisional
wounds in the ears of the MRL/MpJ mouse were found
to regenerate completely after 4 to 5 weeks, whereas in the
control strain, C57Bl/6, the wounds remained and did not
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Figure 1 MRL/MpJ ear 14 days post-wounding
Blastema-like structures either side of the punch biopsy hole. Thickened tip epithelia can be seen along with epidermal
downgrowths (DG), cartilage (C), skeletal muscle and hair follicles (HF). Scale bar, 1 mm.
regenerate. The genetics behind this phenomenon have been
studied, and genomic levelQTLmapping has been performed
[18]. This method demonstrated that candidate genes for ear
regeneration were present on most of the mouse chromo-
somes, but failed to elucidate any true possible genes. Since
that time, further studies have suggested that components of
the inflammatory system may play a significant role in the
regeneration/repair process [19–21].
We have demonstrated considerable variability in the
MRL/MpJ regenerating mouse ear model [22]. The extent
of complete regeneration was dependent on the degree of
trauma imposed, with wounds created by a blunt ear punch
least probable to regenerate compared with those created by
a sharp surgical biopsy punch. Histological analysis suggests
that the regenerative capacity of the MRL/MpJ mouse may
only occur under specific conditions, and in situations where
substantial amounts of necrosis and inflammation occurs, a
default repair mechanism overrides the regenerative mech-
anism. It was also determined that the C57BL/6 control
mouse did possess a limited regenerative capacity,with biopsy
punch wounds closing to just over half their original size by
the end of the time course. This was in contrast with the
original phenotype description of these mice, where no signi-
ficant decrease in wound size was observed in these animals.
MRL/MpJ mice regenerated their ears by developing a
blastema-like structure, similar to the structures seen in
regenerating amphibian limbs (Figure 1; [23–26]). Interest-
ingly, the regeneration was characterized by development of
de novo cartilage islands in the de-differentiated cells of the
mesenchyme (Figure 2A). C57BL/6 wounded ears that did
not regenerate, developed stunted bleb-like projections of
cartilage contiguous with the wound site (Figure 2B; [22]).
Regeneration and repair co-exist in the
same animal
We have recently demonstrated further variability in the
MRL/MpJ regenerative response. Using the same animals in
which the ear punches were created, equivalent 4 mm dorsal
Figure 2 MRL/MpJ and C57BL/6 ear wounds 35 days
post-wounding
(A) Cartilage ‘islands’ clearly visible in the regenerating MRL/MpJ ear,
and (B) cartilage wound edge forms stunted bulbous outgrowth in
equivalently wounded C57BL/6 ears. Scale bar, 200 µm.
skin punch biopsy excisional wounds were also made. On
analysis of those wounds on the dorsal skin of MRL/MpJ
mice, no apparent regeneration occurred (Figure 3). Instead,
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Figure 3 Ear and back wounds in MRL/MpJ mice 112 days post-
wounding
(A) Ear wounds showing epithelial fusion (arrow), and (B) back wound
showing an absence of differentiated structures in the area of the
wound. Scale bar, 500 µm.
in the back wounds, scars of similar size and quality to those
of the control animals (C57BL/6) developed. Analysis of
early macrophage recruitment was found to be the same
between the two strains as was the deposition of α-smooth
muscle actin. This suggests that the mechanism responsible
for regeneration in the ear was not functioning in the skin.
This result was surprising since it contrasts quite markedly
with earlier results observed inMRL/MpJmice obtained after
2 mm through-and-through biopsy punching of the ear
[17,22]. The regenerating blastema-like structures were not
observed in ourMRL/MpJ dorsal skin wounds but were seen
in ear wounds created in the same animals [22]. Significantly,
rather than regenerating like the ears, the dorsal wounds
repaired with scarring. This demonstrates that repair in the
back and regeneration in the ear of the same animal can occur
(Figure 3). This fundamentally important phenomenon sug-
gests that the mechanisms governing these two healing
processes are probably controlled by similar molecules that
diverge in different ways dependent on the location of
injury [4].
Another process known to be used in response to injury
and supposed to have a role in regeneration is apoptosis.
Although little is known about apoptosis in the blastema, re-
cently a study in planarians, has suggested that apoptosis may
be involved in controlling cell numbers, eliminating un-
necessary tissues or cells and remodelling the old tissues of
regenerating body parts [27]. Bcl-2 family proteins are the
main regulators of the apoptotic process, acting either to in-
hibit or promote it [28]. Pro- and anti-apoptotic Bcl-2 family
members should function in harmony to regulate the apop-
totic machinery, and their relative levels are critical for cell
fate throughout development [29–31]. Further study is under-
way to understand the role of apoptosis in the repair and
regeneration observed within the MRL/MpJ mouse.
This lack of regeneration in the dorsal skin is as yet undeter-
mined, but may be a reflection of differences in the architec-
ture of the two sites. The ear is a very thin structure with
epidermis on both sides, as well as containing a supporting
cartilage framework. The blastema-like structures that de-
velop in the wounded ear are manifested adjacent to the
cartilage at the wound edge. It may be that the regeneration of
the ear is in some way controlled by a number of factors, in-
cluding the deposition of new cartilage, glycosaminoglycans
and extracellular matrix within the developing primitive
mesenchyme of the blastema-like structure. In contrast, the
skin on the body is loose, much thicker than the ear and with
a substantial subcutaneous fat layer. Unlike the ear that has
epithelia on both sides, there is only one layer of epithelia in
the back. Contraction of the back wounds probably play an
important role in the repair process, whereas in the ear this
does not occur.
Mechanotransductive forces on cells are known to play a
role in signalling pathways, growth factor shedding and cell
proliferation [32,33]. It is supposed that cells are able to sense
mechanical stress through autocrine loops localized to com-
pliant extracellular spaces [32]. If this is the case, then in
an injury made on the dorsal skin such cellular stresses are
probably much different from the ones that impact on cells
in the injured ear. This phenomenon may play a role in the
subsequent mechanisms governing whether a wound closes
by simple repair or by scar-less regeneration.
In summary, unlike the regeneration observed in the ears
of MRL/MpJ mice, dorsal skin wounds heal with scarring
similar to other strains of mice. The most exciting and signi-
ficant finding of our present studies is that regeneration and
repair can occur simultaneously within the same animal, as
has also been noted to occur in humans [4]. This suggests
that similar molecules and signals are probably required for
both mechanisms but in some way are capable of being
reprogrammed, dependent on the location of injury within
the body.
What will tissue engineers be capable
of making in future?
Similar to all new disciplines, expectation far outways the
initial output, and the time to deliver a fully functional ‘off-
the-shelf’ tissue engineered product is proving to be a lengthy
process. More importantly, even before manufacturing and
automation come into play, scientists need to clarify a number
of critical issues. These include finding good sources of cells
for the engineered tissues and organs, dealing with the im-
mune system’s response to them and their persistence,
improving vascularization of the graft, building better matrix
scaffolds, and learning how to better preserve the organs once
they are constructed. Model experimental animals like the
MRL/MpJ mouse demonstrate subtle differences between
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repair and regeneration and thus hold great hope for the tissue
engineer because they are easily manipulated. Once fully
understood, such model systems may yield an approach that
will ultimately provide answers to some of the critical
problems highlighted in the present study and raise hope
for therapeutic regeneration in humans.
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